Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies ( NASDAQ:TSHA – Get Rating ) in a research note published on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $6.00 price objective on the stock. Several other equities research analysts have also weighed in on the company. Morgan Stanley lowered Taysha Gene Therapies from an overweight rating to an equal weight rating and cut their target price for the stock from $23.00 to $3.00 in a research report on Friday, January 27th.

https://www.dailypolitical.com/2023/04/02/taysha-gene-therapies-nasdaqtsha-given-buy-rating-at-needham-company-llc.html

#dailypolitical